FemCap

What FemCap does

FemCap Inc. is a privately held medical device company incorporated in Michigan and operationally based in Del Mar, California. Founded by Dr. Alfred Shihata in 2002-2003, the company develops, manufactures, and distributes the only FDA-approved second-generation cervical cap contraceptive device available in the United States. The core product is a reusable, medical-grade silicone cervical cap offered in three size variants (Pearl 22mm, Sapphire 26mm, Emerald 30mm) priced between $90 and $270 per unit, intended for use with spermicide gel to deliver 96-98% contraceptive effectiveness under perfect-use conditions.

The company's product architecture centers on an asymmetrical brim design and proprietary removal strap, both intended to improve fit, comfort, and safety relative to traditional diaphragms. The device is approved as a Class III medical device by the FDA and is supported by clinical study data showing 75% preference over the diaphragm among users. FemCap operates a primarily direct-to-consumer go-to-market via its own e-commerce site (femcap.com), supplemented by an integrated telehealth prescription service (FemCap Rx at $39.95 per consultation) and a network of authorized international distributors across the UK, Sweden, Hungary, and the Czech Republic. US customers require a prescription; international customers purchase directly.

FemCap monetizes through one-time product sales of the reusable device (replacement cycle up to two years), consumable spermicide gel (VCF at $22 per package), bundled Rx kits (Emerald + telehealth at $309.95), and clinician demonstration kits supplied free of charge to drive downstream prescribing. The company maintains HIPAA compliance for handling protected health information through its telehealth partnership. Its served customer base consists of individual women seeking hormone-free contraception, with multiple secondary segments including IUD-contraindication patients, breastfeeding mothers, and fertility-awareness users. The company's geographic footprint excludes Canada, and revenue, headcount trends, and ownership stakes (beyond Dr. Shihata's founder role) are not publicly disclosed.

Name

FemCap

Legal name

FemCap Inc.

Website

https://femcap.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

FemCap Inc. is a privately held medical device company that manufactures and sells the only FDA-approved second-generation cervical cap contraceptive device in the US, serving individual women seeking hormone-free birth control through direct-to-consumer e-commerce and an authorized international distributor network.

Ownership category

akta.pro rank

Product category

Women's Health Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYCRABAIAK

Fertility & Ovulation Products (OTC)

Consumer Products & Retail/Beauty & Personal Care/Feminine Care

SECONDARYHLALAHAB

Contraception & Family Planning Telehealth (birth control, counseling, follow-up)

Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)

Keywords

• Cervical cap contraception
• Hormone-free birth control
• Medical-grade silicone device
• FDA-approved contraceptive
• Barrier contraceptive devices

Headquarters

HQ city

Warren

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel, Infrastructure

Revenue model

1. Product Sales: One-time purchase of FemCap cervical cap devices (reusable for up to two years). Additional revenue from complementary spermicide gel (VCF) and telehealth prescription services.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

FemCap designs, manufactures, and sells an FDA-approved, hormone-free cervical cap contraceptive device made of medical-grade silicone. The device is available in three sizes (Pearl 22mm, Sapphire 26mm, Emerald 30mm) based on pregnancy history, is reusable for up to two years, and must be used with spermicide for up to 96-98% effectiveness with perfect use. Supporting offerings include a complementary VCF spermicide gel, a telehealth prescription service (FemCap Rx), and complimentary clinician demonstration kits.

Product overview

FemCap offers a portfolio of hormone-free contraceptive products centered around its FDA-approved cervical cap device. The core product is the FemCap cervical cap, available in three sizes (Pearl, Sapphire, Emerald) determined by pregnancy history, which must be used with spermicide (VCF Vaginal Contraceptive Gel) for effective contraception. Supporting products include the FemCap Rx telehealth prescription service for obtaining prescriptions online, and a clinician demonstration kit for healthcare provider education. The FemCap device is reusable for up to two years and provides up to 96-98% effectiveness with perfect use.

Differentiator

Problem solved

Functional benefit

Brands

• Pearl: The Pearl (22mm) FemCap designed for women who have never been pregnant.
• Sapphire
• Emerald

Products and services

• FemCap Cervical Cap FDA-approved, hormone-free cervical cap contraceptive device made of medical-grade silicone, reusable for up to two years. Available in three sizes (Pearl 22mm, Sapphire 26mm, Emerald 30mm) based on pregnancy history. Used with spermicide for up to 96-98% effective contraception with perfect use. Designed for women seeking non-hormonal birth control.
• FemCap Rx (Telehealth Prescription) Telehealth consultation service that connects US customers with licensed physicians via video to obtain a prescription for FemCap. Sold at $39.95 per consultation, the service is required for US customers to receive the prescription-only device.
• VCF Vaginal Contraceptive Gel

Quantifiable outcome

• 96-98% effective with perfect use when used with spermicide every time
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Bayer (Women's Health): Global pharmaceutical incumbent with a large contraceptive franchise (Mirena, Kyleena IUDs, Yaz, etc.). Competes indirectly with FemCap for the contraception dollar and has vastly greater physician detailing, payer access, and marketing budgets.
• Theramex: Women's health pharmaceutical company focused on menopause, contraception, and reproductive health with a portfolio of hormonal contraceptives. A mid-sized European-focused incumbent that competes indirectly with FemCap in the women's health category.
• Organon: Spun out of Merck in 2021 as a focused women's health pharmaceutical company with a large portfolio of contraceptives (NuvaRing, Cerazette, Nexplanon). A broad incumbent in contraception with global distribution that dwarfs FemCap's reach.
• CooperSurgical: A large women's health medical device company that historically distributed diaphragms (Milex) and other contraceptive and fertility devices. Operates broadly across OB/GYN and reproductive health with much greater scale, sales infrastructure, and clinical relationships than FemCap.
• Pfizer (Women's Health): Global pharmaceutical incumbent with a substantial contraceptive portfolio (Depo-Provera, Loette, etc.). Competes with FemCap across the broader contraception market with significantly greater R&D, regulatory, and commercial resources.

Emerging players

• Natural Cycles: FDA-cleared hormone-free fertility tracking app that targets the same non-hormonal, woman-controlled contraception audience as FemCap. While a software product rather than a device, it competes for the same consumer mindshare among women avoiding hormonal methods.

Direct peers

• Evofem Biosciences (Phexxi): Marks Phexxi, an FDA-approved hormone-free, on-demand vaginal contraceptive gel positioned squarely in the non-hormonal contraception segment that FemCap targets. Both compete for the same consumer (women avoiding hormonal methods), though via different delivery mechanisms (gel vs. cervical cap).
• Caya (Kessel Medintim): Manufacturer of the Caya contoured diaphragm, the most direct competitor to FemCap in non-hormonal, reusable, woman-controlled barrier contraception. Sells globally without prescription in many markets and is the closest functional substitute to FemCap in Europe and internationally.
• Veru Inc. (FC2 Female Condom): Markets the FC2 Female Condom, the only FDA-approved female condom. Competes with FemCap for the same woman-controlled, non-hormonal contraceptive niche with overlapping positioning around autonomy and STI protection.

Others

• Church & Dwight (VCF): Owner of the VCF (Vaginal Contraceptive Film) and spermicide brands that FemCap actually recommends and resells alongside its cervical cap. Functions as a critical ecosystem partner for FemCap's effectiveness rather than a direct competitor, with VCF products being required for FemCap's perfect-use efficacy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/MyFemCap
• Instagraminstagram.com/femcapbirthcontrol
• TikToktiktok.com/@femcapbirthcontrol
• Xx.com/FemCap

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FemCap